JAGX · Jaguar Health, Inc.

Jaguar Health's special meeting resulted in comprehensive stockholder approval of all five proposals, representing significant corporate actions. The authorized share increase from 298 million to 500 million common shares provides the company with substantial flexibility for future equity financing, strategic transactions, or other corporate purposes. The approval of two potential reverse stock splits, with ratios ranging from 1-for-15 to 1-for-150, gives the board discretion to implement significant share consolidation within the next year, potentially aimed at maintaining Nasdaq listing compliance or improving the stock's market perception. The Streeterville Capital note exchange approval facilitates the conversion of existing debt into equity, which could impact shareholder dilution. The strong voting participation (approximately 58% of eligible shares) and decisive approval margins across all proposals indicate stockholder support for management's strategic direction. These approvals collectively position the company with enhanced capital structure flexibility and potential mechanisms to address stock price considerations.